(“RemeGenix”) is a development stage biotechnology company,
focused on the commercialization of disease-altering therapies to prevent
and treat Alzheimer’s disease (AD).
RemeGenix' lead drug, MoBA
represents a novel drug class, a Modulator of
Beta secretase processing of Amyloid Precursor Protein (APP). Unlike the competition, it
allows for the most specific modulation of APP processing, without having the potential for side effects
(see slideshow below for a comparison of MoBA
and other competitive products in development).
Numerous AD drugs developed by our competitors have failed, some with significant side effects, and most recently
one of the drugs even made the patients cognitive impairment worse.
Pre-clinical studies performed using our Novel Models of Alzheimer's and Dementia (NoMAD
have predicted such a failure.
can provide the most specific protection from APP processing, and therapeutically
rescue a patient from cognitive decline and/or deficit associated with faulty biological processes
responsible for cognitive dysfunction.
RemeGenix is dedicated to the development of disease modifying drugs that can be used to treat Alzheimer's and technology platforms that can further the understanding of this complex disease.
RemeGenix lead therapeutics for treating the cause of Alzheimer's disease are Modulators of the Beta Secretase Processing of APP (MoBA).
RemeGenix drug discovery and development platform consists of Novel Models of Alzheimer's and Dementia (NoMAD).